Generic Name and Formulations:
Galsulfase 1mg/mL; conc. soln for IV infusion after dilution; preservative-free.
Indications for NAGLAZYME:
Mucopolysaccharidosis VI (MPS VI).
Adults and Children:
<5yrs: not recommended. ≥5yrs: Give by IV infusion over 4 hours. Initial infusion rate: 6mL/hr for the first hour, then, if tolerated, may increase to 80mL/hr for the remaining 3 hours. May extend infusion time up to 20 hours if infusion reactions occur. Pretreat with antihistamines w/wo antipyretics 30–60mins prior to starting infusion. 1mg/kg once weekly.
Discontinue if severe infusion reactions occur. Antihistamine pretreatment may increase risk of apneic episodes. Risk of acute cardiorespiratory failure in patients susceptible to fluid volume overload (eg, weighing ≤20kg, underlying respiratory illness, compromised cardiac and/or respiratory function). Consider evaluation of airway patency prior to treatment. Acute febrile or respiratory illness: delay infusion. Monitor for spinal/cervical cord compression (including back pain, limb paralysis, urinary and fecal incontinence). Pregnancy (Cat.B). Nursing mothers.
Recombinant human N-acetylgalactosamine 4-sulfatase enzyme.
Rash, pain, urticaria, pyrexia, pruritus, chills, headache, nausea, vomiting, abdominal pain, dyspnea; infusion reactions.
Visit www.MPSVI.com/CSP or call (866) 906-6100 to participate in Clinical Surveillance Program.
Single-use vial (5mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline